Chapter 3
WIA-BIO-020 (version 1.0.0, status Active, category BIO / Biotechnology) is a framework for regenerative medicine: therapies that restore, replace, or regenerate damaged tissues and organs. It covers stem cell therapies, tissue regeneration, organ repair, growth factor delivery, and scaffold engineering. The specification is organized around the biological problem. It names the cells, quantifies what happens to them after delivery, defines the materials that carry them, and describes records, interfaces, and release criteria that make a preparation traceable from the culture dish to the patient. This chapter walks through that structure in five parts. It starts with the cell vocabulary, then the quantitative regeneration model, the scaffold and growth factor layer, the data and API surface, and finally the safety and regulatory envelope.
Every record in the standard begins with a cell type, so the specification defines the four classes it supports and the evidence needed to call a preparation by that name. The table summarizes them as the specification presents them.
| Type | Full name | Source | Potency | Typical application |
|---|---|---|---|---|
| ESCs | Embryonic Stem Cells | Inner cell mass of the blastocyst (day 5-6 embryo) | Pluripotent | All tissue types; disease modeling, drug screening |
| iPSCs | Induced Pluripotent Stem Cells | Reprogrammed somatic cells (fibroblasts, blood cells) | Pluripotent | Patient-specific therapy |
| MSCs | Mesenchymal Stem Cells | Bone marrow, adipose tissue, umbilical cord, dental pulp | Multipotent | Bone, cartilage, muscle |
| HSCs | Hematopoietic Stem Cells | Bone marrow, peripheral blood, cord blood | Multipotent | Blood and immune cells |
The specification attaches identity criteria to each class instead of leaving the label to the producer.
The distinction between pluripotent and multipotent drives most downstream choices. A pluripotent line needs tumorigenicity screening that a multipotent line mostly does not. A multipotent line is checked against a short list of surface markers rather than a teratoma assay. The standard encodes that difference through its quality control lists, not through a single generic checklist.
Regenerative medicine is judged by whether tissue actually rebuilds, so the specification defines a small set of measurable quantities. The core concepts use three formulas.
R = (ΔT / Δt) × E Regeneration rate (cells/day); E = efficiency factor
S = (N_viable / N_total) × 100% Cell survival rate
I = (V_integrated / V_total) × F_vascular × F_mechanical Integration score, 0-1Survival is the simplest check. The reference example is an iPSC preparation with 8,500,000 viable cells out of 10,000,000, which gives S = 85%. The integration score is the strictest measure, because a graft counts only if it is both perfused and mechanically coupled. The score multiplies the integrated volume fraction by a vascular factor and a mechanical factor, so a graft that is well vascularized but mechanically mismatched cannot score highly. The target stated in the specification is I ≥ 0.8.
The mechanisms chapter of the specification breaks regeneration into three cellular pathways and two tissue-level processes.
Read together, these definitions explain why the standard treats vascularization as a first-class concern. A thick construct can have excellent cell viability at implantation and still fail, because the cells inside it cannot be perfused. The vascular factor in the integration score and the vessel density metric exist for that reason.
Cells rarely work alone. The standard pairs them with a structural carrier and with signaling molecules, and it specifies both.
Scaffold design. Five essential properties are listed: biocompatibility, biodegradability matched to tissue growth, porosity of 70-90% for nutrient diffusion, mechanical strength that matches native tissue, and surface chemistry that supports cell adhesion. Porosity is measured as P = (1 − ρ_scaffold / ρ_material) × 100%, and stiffness as Young's modulus E = σ / ε. Target stiffness depends on the tissue:
| Tissue | Target Young's modulus | Pore size guidance |
|---|---|---|
| Bone | 10-20 GPa | 100-500 μm |
| Cartilage | 0.5-2 MPa | 50-150 μm |
| Skin | 0.1-1 MPa | not specified |
| Blood vessels | 1-10 MPa | not specified |
Materials fall into natural and synthetic families. Natural polymers include collagen (enzymatic degradation by MMPs), gelatin, chitosan (lysozyme), hyaluronic acid (hyaluronidase), fibrin (plasmin), and alginate (non-enzymatic, used for cell encapsulation). Synthetic options include PLA (12-24 months), PLGA (1-12 months), PCL (24-36 months), PEG (stable or tunable), and polyurethane (variable). Degradation time is the key selection criterion. A carrier that dissolves before the tissue can bear load, or one that persists for years in a site that should remodel, both defeat the purpose. That is why the error list includes a code for scaffold degradation that is too fast. The fabrication methods listed are bioprinting (50-200 μm resolution, cell viability above 85% after printing), electrospinning (fiber diameter 50 nm to 5 μm), and freeze drying (pore size 50-300 μm).
Growth factors. The specification tabulates nine key factors with function, target cells, and an optimal dose range, and a comprehensive appendix adds molecular weight, half-life, stability, and storage. A selection follows.
| Factor | Function | Optimal dose | Half-life | Storage |
|---|---|---|---|---|
| VEGF | Angiogenesis (endothelial cells) | 10-50 ng/ml | 2-4 h (VEGF-A) | -80°C |
| TGF-β | ECM production (fibroblasts) | 1-10 ng/ml | 2-3 min (TGF-β1) | -80°C |
| BMP-2 | Bone formation (osteoblasts) | 50-200 ng/ml | 7 min | -20°C |
| IGF-1 | Cell growth | 50-200 ng/ml | 12-15 h | -20°C |
| BDNF | Neurogenesis (neurons) | 10-100 ng/ml | 1-10 min | -80°C |
The half-life column explains the delivery design. A bolus injection is simple and acts at once, but concentration decays as C(t) = C₀ × e^(−kt) with a half-life of 2-24 hours for most factors. For factors that last minutes, such as TGF-β1, BMP-2, and BDNF, a single bolus is nearly useless. Scaffold-based delivery follows M_released(t) = M_total × (1 − e^(−kt)) and offers three release patterns: immediate (50-80% in 24 h), sustained (10-20% per week), and programmed controlled release. Microsphere encapsulation (1-200 μm) releases by diffusion, polymer degradation, or osmotic pressure. The practical rule is to choose the delivery vehicle according to the factor's stability. The therapeutic window is stated in the safety rules as 10-100 ng/ml.
The standard's software layer exposes the same quantities as typed requests and responses. It names six required components for any compliant system: cell source management (origin, passage, characterization), differentiation protocols, quality control, a growth factor calculator, a scaffold designer, and a clinical tracker.
The regeneration-rate call takes a tissue type from a closed set (cardiac, neural, bone, cartilage, skin), a cell density in cells/ml, a time frame in days, and a list of growth factors. It returns a rate, a recovery percentage, a time to completion, and a feasibility grade.
interface RegenerationRequest {
tissueType: 'cardiac' | 'neural' | 'bone' | 'cartilage' | 'skin';
cellDensity: number; // cells/ml
timeFrame: number; // days
growthFactors: string[];
}
interface RegenerationResponse {
rate: number; // cells/day
recoveryPercentage: number;
timeToComplete: number; // days
feasibility: 'high' | 'medium' | 'low';
}The survival call mirrors the formula in 3.2 and returns a survival rate from 0 to 100, a qualitative viability grade (excellent, good, fair, or poor), and a list of recommendations. The scaffold call takes tissue type, material, porosity (0-1), size in cm³, and optional mechanical requirements. It returns dimensions, pore size in μm, degradation time in months, predicted mechanical properties, and a biocompatibility grade. The SDK and the command-line tool wrap the same operations. One example is wia-bio-020 calc-regen --tissue cardiac --cells 1e8 --days 14.
Records use JSON. A cell characterization record carries the identity and quality evidence discussed in 3.1.
{
"cellType": "iPSC",
"passage": 15,
"markers": { "OCT4": 0.95, "NANOG": 0.92, "SSEA4": 0.94 },
"viability": 0.89,
"karyotype": "46,XY",
"mycoplasma": "negative",
"doubling_time_hours": 24
}Implementers should note a unit convention in these examples. Marker expression and viability in the record are fractions between 0 and 1, while the survival response reports a percentage from 0 to 100. A tissue regeneration record follows the same pattern for outcomes. A cardiac example holds baseline and post-treatment ejection fraction (0.35 to 0.42) and infarct size (15 to 10 cm²), plus a vessel density of 320 after treatment. The 320 value falls inside the 200-400 vessels/mm² healthy range from 3.2. The record's improvement_percentage of 20 is consistent with the relative change in ejection fraction.
The REST surface exposes this model as resources: preparations (registered and fetched by id), growth factors, clinical applications, QC results, an audit trail per preparation, a safety incident log, and a WebSocket stream for cleanroom telemetry. The audit trail is addressed by preparation id because the preparation is the unit of traceability.
Failures are reported with six standard codes that tie directly to the biology.
| Code | Meaning | Prescribed action |
|---|---|---|
| B001 | Cell contamination detected | Discard culture, decontaminate |
| B002 | Low viability (below 70%) | Optimize culture conditions |
| B003 | Marker expression insufficient | Extend culture, retest |
| B004 | Scaffold degradation too fast | Change material or crosslinking |
| B005 | Growth factor instability | Add stabilizers, reduce temperature |
| B006 | Immune rejection risk | HLA matching, immunosuppression |
Each code names a remedy, so a system can map a failed check to a laboratory action. B002's 70% threshold also matches the viability release criterion in 3.5.
The safety rules are six short statements, and each answers a known failure mode of cell therapy.
Manufacturing parameters turn these rules into numbers. The GMP section sets an ISO Class 5 cleanroom, air with fewer than 3,520 particles of 0.5 μm or larger per cubic meter, temperature of 20-24°C, and humidity of 30-60% RH. It also requires Master Cell Bank characterization, batch production records, and chain-of-custody documentation. The release test table is where a preparation either passes or does not.
| Test | Acceptance criterion |
|---|---|
| Sterility | No growth (14 days) |
| Endotoxin | Below 5 EU/kg body weight |
| Mycoplasma | Negative |
| Viability | Above 70% |
| Identity | Marker expression above 90% |
| Purity | Contaminating cells below 5% |
| Potency | Functional assay specific to the product |
| Karyotype | Normal, where applicable |
On the regulatory side, the specification is written to fit two expedited pathways. In the United States, an RMAT designation requires a regenerative therapy (cell or gene therapy) intended to treat, modify, or cure a serious condition, backed by preliminary clinical evidence of benefit. A designation opens access to programs such as Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval. Submissions include pre-IND documentation, a CMC section, nonclinical toxicology and biodistribution studies, and phased clinical protocols. In Europe, a product falls into one of four ATMP categories: gene therapy, somatic cell therapy, tissue-engineered, or combined. It must demonstrate GMP quality, preclinical safety, clinical efficacy, a risk management plan, and a pharmacovigilance system. The standard also links to related WIA standards for cell culture, tissue engineering, and health monitoring.
The use cases in the specification show the pieces working together:
Summary and connection to the next chapter. The standard has four layers. Defined cell classes with measurable identity criteria form the base. A small quantitative model of survival, differentiation, rate, vascularization, and integration describes what happens after delivery. Scaffolds and growth factors are chosen by degradation time and half-life. Typed records, a preparation-centered API, and six biology-specific error codes carry the information. Around all of them sit the safety rules, the GMP parameters, and the release criteria that decide whether a preparation reaches a patient. The next chapter moves from this overview to the mechanics of putting these definitions to work: how the formulas, records, and checks fit together inside a working system.